cisplatin

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

›

CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	cisplatin + dexamethasone Sensitive: D – Preclinical Front Oncol - 1 week (New D) cisplatin + dexamethasone Sensitive : D Front Oncol - 1wk	cisplatin + dexamethasone Sensitive: D – Preclinical Front Oncol - 1 week cisplatin + dexamethasone Sensitive : D Front Oncol - 1 week - (New D)
CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CPS1 overexpression + KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	cisplatin Sensitive: D – Preclinical Front Oncol - 1 week (New D) cisplatin Sensitive : D Front Oncol - 1wk	cisplatin Sensitive: D – Preclinical Front Oncol - 1 week cisplatin Sensitive : D Front Oncol - 1 week - (New D)
SERPINE1 overexpression	Ovarian Cancer	SERPINE1 overexpression	Ovarian Cancer	cisplatin Resistant: D – Preclinical AACR 2023 - 2 weeks (New D) cisplatin Resistant : D AACR 2023 - 2wk	cisplatin Resistant: D – Preclinical AACR 2023 - 2 weeks cisplatin Resistant : D AACR 2023 - 2 weeks - (New D)
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + docetaxel + 5-fluorouracil Sensitive : A2	cisplatin + docetaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + docetaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive : A2	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2

cisplatin

Associations
(312)

Associations
(312)

cisplatin

Associations(312)

Associations(312)

Associations
(312)

Associations
(312)